Celgene Corporation (NASDAQ:CELG) has tumbled 4.05% during the past week and has dropped 2.68% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.9%. Celgene Corporation (NASDAQ:CELG) has underperformed the index by 3.57% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Celgene Corporation (NASDAQ:CELG): The stock opened at $100.43 on Friday but the bulls could not build on the opening and the stock topped out at $100.43 for the day. The stock traded down to $98.22 during the day, due to lack of any buying support eventually closed down at $98.74 with a loss of -1.49% for the day. The stock had closed at $100.23 on the previous day. The total traded volume was 5,976,683 shares.
The company shares have dropped -15.77% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $140.72 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $103.21 and the 200 Day Moving Average price is recorded at $105.24.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Kaplan Gilla, director of Celgene Corp /De/, had unloaded 15,967 shares at an average price of $101.84 in a transaction dated on April 4, 2016. The total value of the transaction was worth $1,626,079.
Many analysts have stated their opinion on the company shares. Major Brokerage house, BTIG Research downgrades its ratings on Celgene Corporation (NASDAQ:CELG). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 1, 2016. Currently the company Insiders own 0.96% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.05% . Institutional Investors own 81.31% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -24.94%.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.